Aspen Aerogels (ASPN) Status Update summary

Strategic rationale and objectives

• Secured $225 million in debt financing with MidCap Financial to enhance financial strength, flexibility, and support long-term growth, including future project financing for a second manufacturing facility in Georgia.

• Financing aims to lower long-term cost of capital, provide flexibility, and align with future project financing for Plant II.

• Recent record revenue and strong margins supported the ability to secure this financing.

• Incremental liquidity and flexibility are seen as confidence builders for OEM customers, supporting capacity expansion for future demand.

• No significant change in customer engagement process, but improved financial position signals self-sufficiency and reliability.

Financing structure and terms

• $225 million credit facility includes a $125 million term loan and a $100 million revolving credit facility, both maturing in five years, with SOFR-based rates and prepayment penalties for the first three years.

• All-in cost of capital is under 10%, targeting sub-10% average cost of debt.

• $150 million was used to redeem a 9.5% PIK interest convertible note from Koch Industries, removing potential equity dilution and convertible debt overhang.

• Post-transaction liquidity exceeds $100 million, with additional revolver capacity as the asset base grows.

• Collateral structure excludes the Georgia plant subsidiary, enabling separate project financing for Plant II.

Impact on capital structure and future projects

• Updated capital structure positions the company for sub-10% annual cost of capital and greater earnings power for equity holders.

• No convertible debt overhang in new structure, enhancing equity potential.

• The new structure supports potential project financing at U.S. Treasury rates, with repayment expected only after plant commissioning.

• Structure aligns with anticipated supplemental debt for Plant II construction.

• Plant II project loan expected to further reduce cost of capital.